
Sign up to save your podcasts
Or


Max Rye and Evan Appleton of Intertwined Bio join Galaxy Balance to explore one of the boldest ideas in modern biology: borrowing nature’s most extreme traits and translating them into human health.
From horses that resist liver cirrhosis to naked mole rats, bowhead whales, radiation resistant organisms, hibernating animals, and the future of humans in space, this conversation asks what becomes possible when evolution itself becomes a design library. Max and Evan explain how Intertwined Bio is using synthetic biology, gene editing, AI, virtual macrophages, and agentic systems to identify traits from extraordinary animals and test whether those adaptations can be engineered into human cells.
We discuss liver fibrosis, DNA damage repair, innate immune engineering, longevity, space radiation, de extinction, Colossal Biosciences, the future of virtual cells, and the ethical line between therapy and enhancement.
This is a conversation about turning science fiction into biology.
00:00 - Introduction to Intertwined Bio and their innovative approach
01:01 - The origins and motivations of Max and Evan in biotech
04:56 - Scientific foundation: Borrowing traits from long-lived and resilient animals
07:16 - Why now? Recent technological advances enabling these innovations
10:46 - Role of AI in understanding complex biological systems and virtual cell modeling
14:17 - Delivery strategies for genetic modifications in humans
18:19 - Regulatory pathways and ethical boundaries in gene editing
22:25 - The potential of junk DNA variants and regulatory engineering
27:09 - The potential impact on sports animals and broader applications
31:12 - Industry landscape, collaboration, and competition
33:21 - Building a startup: team dynamics, trust, and early steps
35:58 - Insights on other biotech ventures like AstroMech and their directions
38:39 - Space applications: radiation resistance, hibernation, and life support systems
43:01 - Prioritizing targets using AI and high-throughput screening
48:31 - Broader prospects: aging, longevity, and the OZEMPIC effect
52:44 - Focus on innate immune system engineering and virtual cell development
57:15 - Strategies for macrophage gene editing and cell type targeting
1:01:36 - Bottlenecks in lab throughput and cell growth limitations
1:04:30 - The influence of science fiction on biotech innovation and ethical outlooks
1:06:14 - Closing thoughts: science fiction as inspiration and the rapid transition of ideas into reality
In this episode of Galaxy Balance, I sit down with Charles Fracchia to explore the emerging infrastructure layer of synthetic biology. We discuss the future of secure and scalable bioengineering, the role of community laboratories in accelerating innovation, and how biology is evolving into a programmable technology platform. Charles shares the story behind BioBright, the creation of Bio-ISAC, and the broader challenge of building resilient systems for a world where genetic engineering becomes increasingly accessible.
The conversation moves from cyberbiosecurity and open science to AI-driven biological design, scientific culture, and the growing overlap between software engineering and biotechnology. We also explore the long-term future of human enhancement, decentralized science, and how science fiction continues to shape the ambitions of the next generation of builders working at the frontier of biology.
Timestamps:
00:00 - Overcoming cynicism in AI's role in biosecurity
00:40 - Introduction to Charles Fracchia and his pioneering work
02:07 - Charles's background and journey into biotech innovation
04:01 - Balancing classical education with trial-by-fire experience
06:26 - AI as a search tool versus experimental center in biology
08:28 - Developing AI systems for biological experiment automation
11:35 - The founding and evolution of Black Mesa and its mission
14:26 - The importance of digital batch records and AI-assisted QA QC
16:06 - AI's role in drug development, safety, and traceability
18:44 - Ensuring trust and integrity in AI models for biotech applications
22:51 - Addressing data poisoning and ensuring model robustness
24:45 - Strategies for verifying biological data integrity through cryptography and blockchain
33:55 - Future threats like AI-driven bio weapons and safeguarding strategies
42:48 - The importance of operational innovation in accelerating bioeconomy growth
58:25 - Influence of science fiction on biosecurity and innovation
60:11 - Advice for emerging scientists in a rapidly changing landscape
1:02:53 - Closing remarks and future outlook from Charles Fracchia
What if the most powerful form of human optimization has nothing to do with biotech?
In this episode of Galaxy Balance, Cory sits down with Tyler Todt, who has built a platform around physical health, mental resilience, and intentional living. While the world races toward gene editing, AI, and synthetic biology, Tyler focuses on something more immediate: how daily habits, environment, and mindset shape the trajectory of your life.
They explore the tension between technological enhancement and human discipline, from fertility and genetic selection to Neuralink and simulated realities. Along the way, Tyler shares how small, consistent changes transformed his health, marriage, and purpose, and why most people fail by trying to do too much at once.
Timestamps:
00:00 - Small diet tweaks for improved energy and health
00:11 - The value of movement and daily habits in life optimization
00:44 - Introducing Tyler Todt’s background and mission
01:12 - Tyler’s journey from normal life to disciplined optimization
02:17 - Marriage, weight gain, and mental health struggles in the journey
03:08 - Creating intentional rules to improve life quality
04:08 - Mindset shifts for sustainable health improvements
04:45 - Challenges in maintaining motivation and overcoming setbacks
05:02 - Tips for starting small and building routines
06:01 - The neuroscience of habits and pattern creation
07:27 - The importance of grace and balance in biohacking
08:23 - Brain's autopilot and neural pathways in behavior change
09:16 - Ethical debates around reproductive biotech advances
09:43 - The use of stem cells in fertility and new treatments
10:32 - The future of gene editing and embryo selection
13:33 - Ethical considerations of genetic trait modification
15:35 - The potential dangers of designer traits and societal impacts
16:20 - Risks of focusing on narrow breeding goals
16:49 - Natural genetic variation and evolutionary trade-offs
17:09 - The double-edged sword of certain genetic traits like sickle cell
18:16 - Limitations of current genetic understanding and AI's potential
19:16 - Advances in DNA reading, writing, and CRISPR technology
20:03 - The ethical dilemmas of germline modifications and human enhancement
21:26 - The future of human evolution and the possibility of multiple iterations
22:16 - Space exploration, colonization, and interstellar travel
23:05 - The societal and ethical implications of AI-enhanced humans
24:33 - Neural interfaces, Neuralink, and virtual reality futures
25:35 - The allure and dangers of immersive digital worlds
26:13 - The role of genuine human experiences versus synthetic life
27:32 - The societal challenges of technological inequality
28:02 - The quest for extraterrestrial life and the Fermi paradox
39:15 - The potential for hidden advanced technologies and secret projects
40:44 - The vastness of space and the search for alien life
45:57 - Global cooperation and the importance of humanity's future
46:55 - UFOs, alien encounters, and government disclosures
49:40 - Living in a universe of uncertainties and existential risks
50:14 - Science fiction recommendations: The Matrix and beyond
50:53 - Advice for aspiring longevity explorers: control, curiosity, and consistency
52:25 - Mental health, nervous system management, and daily reflection
53:01 - Final thoughts and appreciation for innovative minds in health science
Genome editing has moved from experimental concept to FDA approved medicine in less than a generation. Few people have been closer to that transformation than TJ Cradick.
TJ was one of the earliest pioneers in programmable biology, helping shape the field from the era of zinc finger nucleases through the rise of CRISPR and next generation editing systems. As the second employee and Head of Genome Editing at CRISPR Therapeutics, he helped lay the scientific foundation for Casgevy, the first FDA approved CRISPR therapy. Later, at Excision BioTherapeutics, he worked on some of the first in vivo CRISPR therapies targeting latent HIV reservoirs.
In this episode, we dive deep into the evolution of genome engineering. We explore the transition from protein engineered nucleases to scalable CRISPR guide libraries, and the growing importance of delivery technologies capable of targeting tissues beyond the liver. TJ explains how off target analysis evolved from primitive assays into massively parallel sequencing pipelines and why the future of gene editing depends just as much on delivery and manufacturing as the editing enzymes themselves.
We also discuss the hidden challenges behind FDA approval, the realities of scaling genome editing therapies, the future of in vivo editing, and the ethical questions surrounding human germline engineering.
This conversation is a rare look inside the engineering, regulation, and philosophy of one of the most transformative technologies humanity has ever developed.
· 0:00 - Science Fiction to Science Fact
· 0:23 - Cutting Edge of Science
· 0:37 - Introduction to TJ Cradick
· 1:06 - CRISPR Therapeutics and Beyond
· 1:42 - Early Interest in Science
· 2:12 - Academic Journey
· 3:08 - Transition to Biotech
· 4:04 - Zinc Finger Nucleases
· 5:28 - Evolution of Screening Technologies
· 6:48 - CRISPR Libraries and High Throughput Screens
· 8:07 - New Technologies in Gene Editing
· 9:15 - Off-Target Effects and Assays
· 11:23 - Future Opportunities in Gene Editing
· 13:18 - Regulatory Challenges
· 16:24 - Cost Challenges in Genome Editing
· 18:22 - Manufacturing and Delivery Innovations
· 20:14 - Delivery Challenges and Innovations
· 22:30 - Capsid Design and Blood-Brain Barrier
· 24:01 - Viral vs. Non-Viral Delivery Systems
· 27:19 - IP Limitations and CRISPR Variants
· 30:31 - Target Selection for Therapeutics
· 34:03 - Precise Repair Technologies
· 37:03 - Off-Target Effects in Gene Editing
· 42:31 - Genetic Instability in Edited Cells
· 46:20 - Human Germline Engineering
· 49:19 - CRISPR for Viral Cure
· 51:27 - Regulatory Path Improvements
· 54:20 - Balancing Speed and Safety
· 57:03 - Advice for Future Scientists
What does it actually take to manufacture biology at scale?
In this episode of Galaxy Balance, Cory Smith sits down with Nabiha Saklayen, CEO and co-founder of Cellino, to explore the future of cell therapy manufacturing. Trained in physics and biophotonics, Nabiha is applying principles from semiconductor fabrication to one of the hardest problems in medicine: turning powerful cell therapies into scalable, reliable products.
The conversation dives into the core challenges of iPSC variability, autologous versus allogeneic strategies, and why manufacturing remains the primary bottleneck preventing these therapies from reaching patients. Nabiha explains Cellino’s approach, combining AI, imaging, and laser-based systems to create a closed, automated platform for cell production.
They also explore how AI is reshaping biology, how scientists are evolving into computational operators, and what the future lab looks like as automation and intelligence converge. From Artemis missions to the arrow of time in reprogramming, this episode connects physics, biology, and the long-term future of engineered life.
This is a deep look at the infrastructure layer of biofuturism and what must be true for living medicines to reach the world at scale.
00:00 - The importance of curiosity and bold thinking in science and technology
00:11 - Nabiha Saklayen’s background and childhood fascination with space
02:01 - Her journey through physics, biophysics, and motivations behind her work
03:24 - Early influences from diverse cultures and educational choices
06:17 - How personal loss shaped her scientific focus on biomedicine
08:40 - Insights on Artemis moon mission and space biology innovations
12:27 - Inspiring the next generation: fostering curiosity in children
14:20 - AI as a tool for biology and the significance of large language models
17:03 - The origins of Cellino: applying light-based manufacturing methods
20:22 - Cellino’s optical bioprocess and steps toward clinical-scale production
22:23 - Addressing variability in iPSC reprogramming and quality control
26:32 - Regulatory milestones and FDA collaborations in advanced therapies
30:27 - The role of automation and dashboards in scalable cell manufacturing
36:52 - Visualizing the process from donor cell to differentiated therapy
40:35 - Maintaining sterility and process control in cell banking
45:40 - How AI interfaces with robotics and the role of scientists in automated development
46:04 - The physics of cell removal using bubbles and laser technology
49:20 - How AI and machine learning optimize manufacturing processes and data management
54:54 - Advice for students passionate about science and innovation
57:19 - Future of human creativity and AI partnership in work and art
59:05 - Speculating on the creation or existence of AGI and its first questions
1:00:03 - The influence of science fiction on Nabiha’s worldview and recommended books
What if aging is not a collection of diseases, but a system-level failure we can intervene in?
In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.
Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.
Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at wefunder.com/rejuvenatebio
00:00 - Replacing organs to reverse aging: science fiction or imminent reality
00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers
01:01 - Noah Davidson’s background and mission at Rejuvenate Bio
01:57 - Reprogramming biological systems for systemic healthspan extension
02:41 - The influence of sci-fi on Noah’s interest in space and longevity
03:38 - Space exploration's crossover with biological resilience
05:25 - The societal impact of science fiction on technological progress
07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection
08:16 - The absence of longevity-focused sci-fi and Noah’s motivation
09:12 - Personal story: pet dog inspired Noah’s longevity work
10:33 - Origin of Rejuvenate Bio and its mission to treat aging
11:57 - Combining gene therapies targeting multiple age-related diseases
13:44 - The potential and limitations of epigenetic partial reprogramming
14:14 - Upcoming clinical trials and safety considerations for gene therapy
16:01 - Cyclic gene therapy and risks of permanent expression
17:43 - Inducible gene expression systems: safety and practical considerations
21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient
22:33 - Strategies for pet therapies and expanding to human applications
25:47 - Manufacturing innovations reducing costs for wide-scale treatment
27:12 - Prophylactic use of gene therapies in pets and humans
29:08 - Targeting multiple diseases with a single systemic therapy
30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts
33:42 - Disease-modifying treatments for fibrosis and heart failure
36:48 - How AAV vector delivery works and safety measures in tissue targeting
42:47 - Regulatory pathways for animal therapies and translational relevance
44:22 - Challenges in funding and VC environment for longevity startups
45:45 - The strategy of using animal models as a bridge to human therapies
50:05 - Future scientific directions: partial reprogramming and cell replacement tech
52:37 - The concept of longevity escape velocity and current progress
53:44 - Personal longevity practices: exercise, diet, sleep, stress management
55:27 - The role of biometric feedback devices in health monitoring
56:54 - Emerging modalities and innovative approaches in anti-aging research
58:24 - The ship of Theseus analogy for cell and tissue replacement
59:37 - Philosophical questions about consciousness and identity in aging
1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts
1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation
1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs
Synthetic biology is entering a new phase where biology can be treated as an engineering discipline. In this episode of Galaxy Balance, Cory Smith speaks with Dr. Tae Seok Moon, professor at the J. Craig Venter Institute and a leader in synthetic biology, about the long arc from reading DNA to eventually designing biological systems from first principles.
Tae shares his unconventional path into science. As a student in Korea he originally wanted to be a poet before choosing chemistry and engineering. that early philosophical curiosity about existence ultimately drew him toward biology and the story of life emerging from molecules after the Big Bang.
The conversation explores the evolution of synthetic biology through a literary metaphor. DNA sequencing allowed scientists to read the letters of life. Genome synthesis made it possible to write those letters. Gene editing introduced a way to revise existing text. Moon argues that most of modern biotechnology still resembles editing or copying nature rather than true creative writing in biology. Only recently have tools such as AI-guided protein design begun to generate entirely new biological "words."
Moon also discusses the legacy of Craig Venter and the creation of the first cell controlled by a synthetic genome. That milestone demonstrated that digital DNA stored in a computer can be turned back into a functioning biological system, a reversal of sequencing that points toward a future where genomes become programmable substrates.
The episode then moves into Moon's work at the intersection of space exploration and biotechnology. His team demonstrated that bacteria can produce the antioxidant lycopene in simulated microgravity using resources that would be available on the Moon or Mars. The system converts plastic waste into a carbon source and processes nutrients derived from human waste to fuel microbial production, a concept aimed at enabling sustainable life support systems during long-duration space missions.
Beyond space exploration, Moon leads global collaborations focused on transforming waste streams into useful chemicals and materials. He argues that the constraints of space missions mirror the resource challenges facing Earth today, from plastic pollution to carbon emissions. Technologies developed for closed-loop life support in space may also help build circular bioeconomies of Earth.
The conversation also tackles the rapid rise of artificial intelligence in biology, the future of scientific publishing, and the challenge of maintaining human creativity in an era of AI-generated research and communication. Moon reflects on what may remain uniquely human: genuine motivation, emotion, and the drive that comes from purpose and connection.
The episode closes with a story about one of Moon's former students who overcame severe adversity and later helped lead the development of a COVID vaccine. For Moon, that journey captures the deeper motivation behind science. The next generation of researchers will face immense challenges, but their work will shape the technologies that improve life across the planet.
This episode explores the frontier where biology becomes designable, where microbes may help sustain human life beyond Earth, and where the language of DNA may one day evolve from editing nature to composing entirely new forms of life.
0:00 - Introduction
1:01 - Tae Seok Moon Background
2:34 - From Poet to Scientist
8:26 - DNA as Language & Creation
12:37 - Synthetic Cells & Venter
18:31 - Microbes in Space
25:47 - ISS & Space Experiments
29:22 - Closed Ecosystems Challenge
32:25 - Solving Global Problems
37:44 - Science Fiction Influence
40:36 - AI in Synthetic Biology
50:38 - Future of Scientific Publishing
1:01:10 - Advice for Young Scientists
What if biology could be engineered the way we engineer software?
In this episode of Galaxy Balance, I'm joined by Pranam Chatterjee, Assistant Professor at the University of Pennsylvania and leader of the Programmable Biology Group, working at the intersection of AI, synthetic biology, and next-generation therapeutics.
Pranam's work is shaping a future where generative models can design peptides and biologics from sequence data alone, enabling a new era of programmable medicine.
We explore how Pranam went from studying religion and philosophy to transferring into MIT and building cutting-edge computational tools for biology. We dive into his time in George Church's lab, where early computational strategies helped spark the origins of Gameto, and how that work evolved into today's iPSC-derived ovarian support cell technologies now entering clinical trials.
From there, we go deep into the frontier of AI-driven molecular design:
• Do we actually need protein structure to design effective therapeutics?
• How do we optimize binding, toxicity, permeability, and immunogenicity simultaneously?
• What does "virtual cell" really mean, and why does mapping cell states matter?
• How close are we to "vibe coding biology," where natural language becomes the interface to biological engineering?
We also discuss the future of automation, robotics, and agentic AI in biology, as well as the ethical risks of democratized generative models in biotech.
This conversation is a window into the net phase of human capability: not just ready biology, but designing it.
00:00 - Introduction to AI-driven therapeutic peptide design
01:05 - Background of Pranam Chatterjee's journey from religion to science
02:50 - The evolution of AI models in synthetic biology
05:17 - Key milestones: from modeling to clinical applications like Gameto
08:19 - The founding story of Gameto and major breakthroughs
12:20 - Expanding into disease targeting and regenerative medicine
17:50 - The shift to virtual cell and organism design
22:16 - Tools for peptide design: Peptune and PEPMLM
25:04 - Generative modeling with language models and functional constraints
28:32 - Imagining programmable organisms and mythical creatures
29:41 - Hardware importance and future of vibe-coded biology
31:54 - The role of automation and robotics in biotech labs
33:47 - Mentoring students for the AI-biotech revolution
36:50 - Targeting rare diseases and regulatory considerations
40:34 - Global competition, safety, and ethics in biotech innovation
44:44 - Designing molecules with AI: from complexity to deliverability
45:09 - Data needs: where to find diverse biological datasets
47:49 - The rise of AI agents in scientific research
50:12 - Ethical responsibilities in AI bioengineering
52:38 - Safeguards against harmful biotech applications
55:22 - Thoughts on artificial general intelligence and human purpose
58:40 - How science fiction inspires biotech innovation
1:00:13 - Book recommendations and closing thoughts
In this episode of Galaxy Balance, Cory Smith speaks with Dr. Jonathan Scheiman, co-founder and CEO of FitBiomics, about the science of elite performance, microbiome discovery, and the future of metabolic health.
Jonathan shares his journey from Division I basketball player to biomedicine PhD and postdoctoral researcher in the Church Lab, where unconventional ideas are encouraged and ambitious biology is the norm
His central question was simple but radical: instead of studying disease, what if we studied peak human performance?
That question led to a longitudinal study of Boston Marathon runners, where his team collected microbiome samples before and after intense endurance events. The data revealed a striking pattern. One microorganism, Veillonella, spiked in abundance immediately after the marathon
Further analysis showed that this microbe uniquely metabolizes lactate and converts it into short-chain fatty acids such as propionate
Lactate is often misunderstood as a fatigue molecule. In reality, it is a normal metabolic fuel. When produced in excess during intense exercise, it accumulates in the bloodstream. Scheiman’s work suggests that a portion of circulating lactate is shuttled to the gut, where Veillonella uses it as a carbon source, producing metabolites that may support mitochondrial function, muscle recovery, glucose utilization, and anti-inflammatory pathways
The episode explores:
• How elite athletes may represent a rare biological phenotype comparable in rarity to centenarians
• Why the microbiome can shift rapidly in response to exercise intensity
• The challenges of culturing and scaling strict anaerobic microbes for commercialization
• The regulatory pathway differences between therapeutic microbiome interventions and consumer health products
• How AI and machine learning enabled the discovery of novel microbial signals in complex datasets
The conversation expands into longevity, mitochondrial efficiency, digital health integration, and the idea of FitBiomics as a biological data company rather than simply a probiotic brand
Scheiman also reflects on science fiction, pop culture, and storytelling as forces that shape technological ambition, drawing connections between Marvel, AI, and biotechnology innovation
This episode sits at the intersection of microbiome science, metabolic optimization, artificial intelligence, and the long-term future of human performance.
If the biology of elite athletes can be decoded and translated, the implications extend far beyond sport.
00:00 - Introduction to microbiome insights for human performance
02:20 - Personal journey from sports to biotech innovation
05:28 - How elite athletes inspired microbiome research
09:04 - Approaching human performance limits and societal health impacts
13:48 - Early discoveries: microbiome sampling from Boston Marathon runners
27:19 - The breakthrough finding: Vianella's role in fatigue and endurance
30:19 - Scientific steps to isolate and validate Vianella
33:29 - Regulatory considerations for microbiome supplements versus therapeutics
36:04 - Prevalence of Vianella across different athletes and individuals
40:51 - Microbiome as a dynamic, modifiable biomarker for health and sport
45:37 - Metabolism, mitochondria, and longevity interconnected through microbiome dynamics
49:16 - Influences of science fiction on biotech imagination and vision
57:39 - Future applications: wearables, continuous monitoring, and AI in microbiome health
1:00:46 - Vision for FitBiomics’ role in health innovation and societal impact
Biology is becoming programmable.
In this episode of Galaxy Balance, Cory Smith speaks with Yuanhao Qu, President and Co-Founder of PhyloBio, about the emergence of AI driven biological discovery. Yuanhao represents a new generation of scientists who combine genome engineering with large language models to build systems that can reason about DNA and accelerate research across the life sciences.
The conversation explores Yuanhao’s journey from early cancer research to developing CRISPR-GPT and Biomni, tools designed to help scientists design experiments, analyze data, and navigate the growing complexity of biological research. The discussion then moves to the founding of PhyloBio and the idea of an integrated biology environment where AI agents collaborate with human researchers.
We examine the future of genome engineering, the challenges of delivering gene therapies, and how AI agents may soon assist in designing experiments, generating hypotheses, and exploring massive biological datasets. They also discuss the possibility of automated laboratories, the evolving role of scientists in an AI-augmented research ecosystem, and the ethical boundaries that must guide advances in synthetic biology.
The episode closes with a discussion of science fiction, biosecurity, and the long term vision of AI systems that help humanity understand life at every scale.
If biology becomes a language, the next frontier will belong to those who learn how to speak it.
Phylo is a research lab developing cutting-edge agentic intelligence to accelerate discovery for biomedical scientists. They are building Biomni Lab, an integrated biology environment that leverages the latest AI to transform how biologists work. Explore it at biomni.phylo.bio
Phylo is also actively hiring. Learn more at phylo.bio/careers
Timestamps:
00:00 - Embracing rapid change and AI tools in biology
02:24 - Yuanhao’s background and motivation to cure cancer
04:11 - Analyzing complex diseases with genomics and AI
07:25 - Switching focus to AI-guided discovery and CRISPR engineering
12:13 - Building and deploying CRISPR-GPT to democratize gene editing design
16:23 - How AI enhances the role of scientists rather than replacing them
20:52 - The story behind PhiloBio and its vision to accelerate biotech innovation
24:01 - Developing BioOmni: an AI environment for biological research
28:21 - The future of AI in autonomous labs and the challenge of human-in-the-loop systems
36:33 - Ensuring safety and predicting oncogenic risk in genome engineering
42:49 - Advances needed in delivery mechanisms for gene therapies
45:02 - Insights into human intelligence evolution and AI’s role in discovery
51:04 - The significance of memory, personalization, and continuous learning in AI agents
55:06 - Ethical dilemmas in human germline modification and societal impacts
58:30 - Speculations on life’s prevalence in the universe and the Dark Forest hypothesis
59:46 - Advice for aspiring scientists eager to innovate with AI
From the publisher's feed
Galaxy Balance explores the frontier where biology, technology and consciousness meet. Each episode brings together pioneers shaping our collective future, from genome engineers and AI builders to…